Project title: Evaluation of 225Ac-DOTATATE for treatment of lung carcinoid tumors

David Morse, PhD Moffitt Cancer Center

David Morse, PhD
  • Status: Active
  • Year(s): 2018
  • Grant Type: Pilot
  • Research Type: Translational
  • Primary Site: Lung
  • Area of Inquiry: Clinical trials

General Description

Researchers will test a novel radiotherapy, 225Ac-dotatate, a derivative of 177Lu-dotatate in PRRT for lung NETs in laboratory models. This therapy emits alpha (α) particles instead of beta (β). Alpha particles are bigger, higher powered, with a shorter reach, which researchers hope will be more effective in killing lung NET cells with decreased toxicity in surrounding normal tissues. Laboratory tests will help evaluate the therapy’s safety and efficacy to prepare for potential testing in humans.

Additional Details

  • City: Tampa
  • Grant Duration: 1 year
« Back to all funded research projects